[(accessed on 18 January 2024)];2023 Available online: 86.Novo Nordisk A/S Efficacy and Safety of Co-Administered Cagrilintide and Semaglutide (CagriSema 2.4 Mg/2.4 Mg) Once Weekly versus Semaglutide 2.4 Mg, Cagrilintide 2.4 Mg and Placebo in People with Chronic Kidney Disease and Type 2 Diabetes Living with Overweight or Obesity
The Journal of Clinical Endocrinology & Metabolism, 91 (12), 4792-4797
Molar Incisor Hypomineralisation: Current Knowledge and Practice
Ferroptosis-inducing nanomedicine and targeted short peptide for synergistic treatment of hepatocellular carcinoma
The preservative assists in inhibiting bacterial growth when withdrawing from this vial
Fabbri M, Beracci A, Martoni M, Meneo D, Tonetti L, Natale V